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Structured Abstract 
Objective 
To weigh the benefits and harms of detecting and pursuing incidental fmdings on 
computed tomographic colonography screening in average-risk populations. 
Data Sources 
I searched MEDLINE, EMBASE, ScienceDirect, and the Cochrane Collaboration 
library from 1996 to present, with all searches limited to English language studies. 
Study Selection 
I developed inclusion and exclusion criteria to examine an average-risk 
population. 
Data Extraction 
I performed a single data extraction from included studies of fair to good quality 
for the preparation of evidence tables. I rated the quality of the selected studies using 
criteria modified from those recommended by the USPSTF for study appraisal. 
Data Synthesis 
Key Question #1: What is the prevalence of all incidental findings detected 
on CTC? At least one extracolonic finding was detected in 62% of screened patients. 
5.9% of patients received additional investigations. One study examined the effects ofiV 
contrast-enhancement. This study reported a lower frequency of patients receiving 
additional investigation than any of the other studies. 
Key Question #2: What is the prevalence of specific types of incidental 
findings? Two studies reported the specific types of findings that were ultimately 
diagnosed. The most common diagnosed pathologies reported in these studies were 
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nonmalignant tumors (1.5% of screened populations), malignant tumors (0.5% of 
screened populations) and aortoiliac aneurysms (0.3% of screened populations) 
Key Question #3: What are the beneficial outcomes of detecting and 
investigating incidental findings? Three studies reported a total of 114 patients (at least 
2.3% of all patients) who received clinical diagnoses. It is uncertain how many of these 
received treatment, but at least 0.9% of all patients received treatment. The true benefit 
of pursuing incidental findings is unlikely to include all of the diagnosed and treated 
pathologies. 
Key Question #4: What are the harms of detecting and investigating 
incidental findings? One study reported the number of patients who received additional 
workup with no reported diagnoses. Underestimated extrapolated values were obtained 
for two studies. Approximately 3.1% of the patients from these three studies received 
additional workup with no reported important clinical diagnoses; this value may 
overestimate the true value. Three studies reported data on invasive procedures that 
resulted in benign findings. At least 0.5% of patients in these three studies received an 
invasive procedure that resulted in the diagnosis of a benign finding. All of the patients 
who receive further investigations with no diagnoses or treatment experience at least 
some degree of harm. 
Key Question #5: What are the costs and cost-effectiveness of detection and 
further investigating incidental findings? The cost of pursuing incidental findings 
likely falls between $98.56 and $248. Cost-effectiveness analysis cannot be assessed 
without a more comprehensive evaluation of the benefits and harms. 
Conclusion 
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Incidental fmdings are found in over half of asymptomatic patients who are 
screened by CTC. The number of patients who receive additional investigations is much 
fewer. A small percentage of patients receive clinical diagnoses and treatment. Clinical 
benefit likely results from some, but not all, of these patients receiving diagnoses and 
treatment. Likewise, a small percentage of screened subjects received additional workup 
with no reported diagnoses. All of these received at least some degree of harm. The 
degree of benefit and harm resulting from each diagnoses, treatment, or additional 
workup remains unclear. This further complicates the task of weighing the benefits 
versus the harms. Available data is insufficient to appropriately weigh the overall 
benefits versus the overall harms. 
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Introduction and Background 
The Problem 
Scn:ening is the strategy used to detect disease or risk factors for a disease in 
individuals without sigus or symptoms of the disease. 1 Screening tests are imperfect. 
Their ability to detect targeted pathology is accompanied by the ability to detect non-
targeted, or incidental, findings. As a screening test's sensitivity (ability to detect true 
positive fmdings) increases, so does its tendency to detect other non-targeted findings. 
Because of this attribute, the overall value of a screening test depends not only on its 
ability to detect the targeted pathology, but also on the consequences of detecting non-
targeted lesions. 
In recent years, researchers have explored the feasibility of using highly sensitive 
tests, such as CT and MRI, as widespread screening tools with the ultimate hope of 
providing improved outcomes. Several large scale CT screening studies have been 
conducted for colorectal and lung cancers, and the American Cancer Society now 
recommends MRI as an adjunct screening tool in women at high risk for breast cancer? 
CT imaging furthermore portrays data on body regions that include much more than the 
targeted organs. Because of this, CT imaging has the ability to detect untargeted, or 
incidental, fmdings.3 An incidental finding is generally defined as an abnormality not 
related to the indication for obtaining a test.4 Concerning CT, "every abnormal fmding 
not directly related to the pathophysiology of the targeted disease should be regarded as 
incidental." 4 The ability to detect these subtle abnormalities has come with an increased 
likelihood of incidental findings, calling more attention to the uncertain consequences of 
4 
their detection. This systematic review addresses the consequences, both benefits and 
harms, of CT screening for colorectal cancer. 
Evaluation of Screening Tests 
An understanding of the basic principles of diagnostic test interpretation gives 
perspective to the detection of incidental findings. The predictive value of a diagnostic 
test- the probability of disease given the results of a test- is not a property of the test 
alone but is also dependent on the prevalence (or pretest probability) of disease in the 
population being tested. Because the prevalence of most diseases, particularly those 
found incidentally, is low in asymptomatic populations, the positive predictive value is 
low, even for tests with high specificity. Positive results, when applied to patients with a 
low likelihood of having the disease, will largely be false positives.1 
The interpretation of a positive or negative diagnostic test result varies from 
setting to setting, according to the pretest probability of disease in a particular setting.1 
Colorectal cancer possesses a sufficient prevalence in the general population of men and 
women aged 50 to 755 in which a screening program can provide more benefit than harm. 
Incidental fmdings, on the other hand, are not detected in a specific population in which 
their true disease states are more prevalent but are instead discovered in a population with 
a negligible pretest probability6, increasing the probability of a positive test to be false. 
Colorectal Cancer Screening 
The ultimate goal of cancer screening is to decrease cancer-related mortality and 
to improve quality of life by detecting curable cancer in its preclinical state. Therefore, 
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in addition to an effective screening tool it is also important to have a treatment whose 
efficacy is greater in the preclinical (asymptomatic) phase than in the clinical 
(symptomatic) phase for a screening program to be effective. 
Randomized controlled trials have found that the efficacy of colorectal cancer 
screening with fecal occult blood testing (FOBT) has been demonstrated to reduce 
colorectal cancer mortality by 15% to 33% in randomized, controlled trialsY·9 The 
relative mortality reduction for colonoscopy screening is unknown, but is presumed to be 
larger than FOBT. During their 2002 systematic review, the U.S. Preventive Services 
Task Force (USPFTF) did not find any screening trials of colonoscopy but analyzed data 
from the National Polyp Study and a case-control study to draw these conclusions.1° For 
these evidence-based reasons, screening guideline recommendations for colorectal cancer 
are widely accepted. 
Problems with Colonoscopy 
Colonoscopy, the gold standard for colorectal cancer screening, carries a variety 
of problems. Major medical risks associated with colonoscopy include damage to the 
colon or rectum, including perforation, adverse reaction to medications (largely sedation 
medications), serious infection, and cardiovascular complications. The main limit to 
colonoscopy screening effectiveness is poor adherence.11 Many factors contribute to the 
lack of adherence to a screening colonoscopy regimen. These include discomfort with 
the invasiveness of colonoscopy and the potential for such serious complications as 
perforation or severe bleeding. In addition to the medical complications and lack of 
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adherence, colonoscopies are costly, averaging $3323-$5000 or morell per procedure in 
the hospital setting. 
Potential Benefits of Computed Tomographic Colonography 
Computed tomographic colonography (CTC) is a promising tool that has the 
potential to help increase overall participation in screening of the population.12 In 
contrast to conventional colonoscopy, the CTC procedure is less time-consuming and is 
less invasive. No sedation is required and the patient can return to his/her usual activities 
after the procedure without the aid of another person. Although CTC does require the 
same pre-procedural preparation as colonoscopy (colonic cleansing and insufflations ), the 
degree of perceived discomfort is much less than that of the invasive colonoscopy. The 
implementation of a CTC screening program aims to decrease the number of standard 
colonoscopies performed per patient screened. Only those patients with polyps identified 
on CTC will be sent for standard colonoscopy and polyp resection. By offering the 
advantage of a "very low" risk of bowel perforation5 compared to conventional 
colonoscopy, many researchers are optimistic that such a program will reduce the number 
of complications per patient screened. 
CTC has been shown to be effective in detecting colonic lesions in the 
asymptomatic population.13 In a 2008 systematic review for the United States 
Preventive Service Task Force (USPSTF), Whitlock et al examined 7 studies examining a 
total of 4468 average-risk patients screened for colorectal cancer with both CTC and 
conventional colonoscopy. Three of the studies did not contribute to quantitative test 
performance analysis due to study design limitations. 5 The two largest and most 
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applicable studies, which accounted for 87% of the observed patients, were those by 
Pickhardt eta! and by the American College of Radiology Imaging Network (ACRIN). 
These studies found that the performance of CTC was comparable to conventional 
colonoscopy for detection oflarge polyps (::>:lOmm) with a pooled sensitivity of92% (CI, 
87% to 96%) and no statistical heterogeneity.5• 14• 15 
Uncertainties of CTC 
Though CTC carries a much decreased risk of many medical complications 
associated with colonoscopy, it holds a different set of underexplored uncertainties. 
Uncertain effects associated with CTC include potential long-term sequelae from 
radiation exposure and potential sequelae from the workup of incidental findings. 15 
CTC examines the entire abdomen, pelvis3, and sometimes the lower thorax16 
allowing the demonstration of both luminal and extralurninal structures. Some have 
suggested that detection of nontargeted fi,ndings is an advantage.17• 18 Serracino-Inglott 
et a! concluded that "CT colonography has good patient compliance and is a useful 
diagnostic modality in detecting colorectal neoplasms. Its main advantage over other such 
investivgative tools is its ability to detect extracolonic pathology."18 
Pickhardt and colleagues, however, have described the ability to detect incidental 
findings as "a potential double-edged sword."19 While detection does confer the 
potential benefits of reassurance and discovery of significant treatable pathology at early 
presymptomatic phases, it carries much potential harm. These potential harms include 
incidental findings with associated anxiety and unnecessary workup. Diagnostic tests 
carry risks. 20 These further workups, sometimes invasive, are often costly and may 
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result in iatrogenic morbidity.21 With consideration of the potential benefits and 
potential harms in light of the epidemiology of disease in low-risk groups, it is important 
to keep an elementary question in the forefront of our thoughts - does CTC produce more 
benefit than harm? 
The economic impact of a widespread CTC screening program remains uncertain 
for two chief reasons. First, we can only hypothesize the effect that such a program will 
have on adherence to screening recommendations. While improved adherence to colon 
cancer screening will confer health benefits, an unexpected extreme improvement may 
present a great economic challenge. Second, we do not yet know how to handle 
extracolonic findings (ECFs) appropriately. 
Importance 
CTC is a rapidly developing practice21 that has a potential future role in screening 
for colorectal cancer.22 Incidental ECFs in CTC are a challenge, however. Applied as a 
widespread screening modality, CTC screening carries the inevitable responsibility of 
handling a large number of incidental fmdings. The accuracy of CTC in detecting 
luminal lesions has undergone considerable evaluation; however the issue of how to 
handle the incidental fmdings is limited and requires further analysis.23 
In 2002, the USPSTF stated that there was insufficient evidence to recommend 
for or against CTC as one of the screening modalities. A 2008 guideline released by a 
joint committee consisting of the American Cancer Society, the US Multi-Society Task 
Force on Colorectal Cancer, and the American College of Radiology incorporate CTC as 
an option for asymptomatic colorectal cancer screening.24 However, in the 2009 
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USPSTF update, the Task Force stated that it is still too early to include it in screening 
recommendations. In February of2009, the Centers for Medicare and Medicaid Services 
(CMS) issued a proposed national coverage decision memorandum not to reimburse for 
CTC for screening purposes.25 Among other grounds, this memorandum includes the 
uncertainty of ECFs, stating "Since extracolonic findings are common, evidence based 
standards and guidelines on reporting, monitoring and subsequent evaluation of these 
fmdings are needed. "25 
Clarification of how frequently incidental findings occur, how best to investigate 
them, and a fuller understanding of the consequences of their detection are necessary to 
appropriately evaluate the benefits and risks of CTC screening. A comprehensive 
evaluation of the frequency and consequences- both benefits and drawbacks- of the 
detection of incidental findings should play a significant role when comparing these 
modalities to other screening methods for large scale screening programs. 4 This paper 
will not direct its concern to the overall utility of CTC screening, but will focus on the 
consequences of further investigation of incidental findings. The objective of this review 
is to assess the clinical consequences - the benefits, risks, and fiscal impact - of pursuing 




The objective of this review is to assess the clinical consequences of pursuing 
nontargeted unanticipated findings from CT colonography screening. A more thorough 
understanding of how to handle these incidental findings along with the consequences of 
their detection is necessary for a more comprehensive analysis of the benefits and harms 
of large scale screening programs. Identification of incidental findings has served as an 
adjunct selling point for advocates of these screening methods17• 18 despite a lack of 
evidence that their detection affords more benefit than harm. Previous reviews3• 5• 26 have 
assessed further investigations of incidental findings found in both asymptomatic and 
symptomatic patients for these screening modalities. This review is not intended to 
comprehensively evaluate the consequences of incidental findings for these imaging 
modalities, but is meant to be analyzed for asymptomatic populations who are described 
recommended populations for screening tests. 
Inclusion and Exclusion Criteria 
Prior to probing data, I generated a list of inclusion and exclusion criteria (Table 
I). Only studies with a clearly defined population were used. In an attempt to strengthen 
external validity for screening assessments, I used target populations that are comparable 
to populations that these large scale screening programs would target. For this reason I 
included asymptomatic individuals and excluded symptomatic individuals from the 
targeted population as testing in symptomatic populations would be categorized as 
diagnostic evaluation rather than screening. I included individuals at normal risk for 
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colorecta1 cancer and excluded individuals at increased risk; this includes patients with 
inflammatory bowel disease, a personal or family history of colorectal cancer or 
colorectal polyps, and genetic syndromes such as familial adenomatous polyposis (F AP) 
or hereditary non-polyposis colorectal cancer.27 I excluded studies that included only 
frail elderly populations. The prevalence of extracolonic fmdings in this elderly 
population might be expected to be increased partly due to age alone, but also because the 
clinical presentations of many conditions are often non-specific in this age group. 23 
I limited the outcome to those studies that included data on further workup of 
incidental findings. Research designs included primary clinical studies and systematic 
reviews, studies of more than 100 consecutive research subjects, and studies with 
methods or results sections defining significant incidental findings. I excluded case 
control studies because these may overestimate the scale of consequences as a design-
related source of bias. I considered only technologies that used a multidetector scanner, 
necessary to produce images of the colon without gaps. 
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Table 1 Inclusion and Exclusion Criteria . 
Inclusion Exclusion 
Population 0 Clearly defmed population 0 Symptomatic patients 
0 Asymptomatic patients at average 0 Populations at high risk for 
risk for colorectal cancer colorectal cancer* 
0 No gender limits 0 Studies dealing specifically with the 
0 No limits on region frail elderly** 
0 consecutive subjects 
Setting 0 CT used for screening of 0 CT used for diagnostic purposes 
colorectal cancer 0 PET scans and other diagnostic 
imaging modalities 
Date & 0 1996 to present 
lan2Ua2e 0 English only 
Outcome 0 All incidental findings with 0 False positives 
analysis of further workup 0 Overdetection 
Research 0 Randomized controlled trials 0 Case series 
design 0 Quasi-experimental studies 0 case-control 
(including non-randomized 0 case reports 
controlled studies) 
0 systematic reviews 
0 cohort studies 
0 cross-sectional studies 
* Risk factors for colorectal cancer mclude mflammatory bowel disease, a personal or famtly history of colorectal 
cancer or colorectal polyps, and genetic syndromes such as familial adenomatous polyposis (F AP) or hereditary non-
polyposis colorectal cancer 27 
**Studies were only excluded if they dealt specifically with the frail elderly. Exclusion of this population was not a 
criterion for study inclusion. 
Literature Search and Retrieval Process 
Databases and Search Terms 
I identified studies by searching electronic databases including PubMed, 
Embase/Ovid Direct, ScienceDirect, and the Cochrane Database. I included articles from 
1996 to present that were available in English only. I included primary clinical studies 
that included data of follow-ups. I identified three systematic reviews that addressed the 
consequences of incidental extracolonic lesions on CTC. 3• 5• 26 Details of search terms, 
strategies, and results are illustrated in detail in table 2 and table 3. 
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Table 2. Medline search terms, strate!rles, and results 
#I Incidental findings 4360 
#2 Incidental discoveries 4370 
#3 Incidental lesions 1565 
#4 Extracolonic fmdings 474 
#5 Extracolonic lesions 120 
#6 #1 OR#2 OR#3 OR#4 OR#5 5665 
#7 Colonography, Computed Tomographic 983 
#8 CT colonography 1110 
#9 Colonography 1229 
#10 Virtual colonoscopy 1242 
#11 Colography 27 
#12 CT colonoscopy 1088 
#13 CT pneumocolon 14 
#14 #7 OR#8 OR#9 OR#IO OR#ll OR#l2 OR#l3 2049 
#15 #6AND#14 82 
Table 3. Results from other electronic databases 
Databases Additional Results 
ISI Web of Knowledge 64 
EMBASE/OVID 2 
ScienceDirect 0 
Cochrane database 0 
Article selection & review 
I conducted the study selection in two stages. I performed an initial screening of 
titles and abstracts against the inclusion criteria to identifY potentially relevant papers. I 
subsequently screened the full papers that I identified as possibly relevant from the first 
screening. I examined titles and abstracts and selected those that mentioned evaluating 
further workup of incidental fmdings for CTC. I evaluated abstracts for inclusion or 
exclusion and obtained the full texts of all articles that had potential to be included in the 
review. I independently reviewed the abstracts and full texts. Double review, though 
desirable, is not feasible for the purposes of this independent project. I exported the 
retrieved references to the Reference Manager- Ref Works. 
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Evaluation of Quality 
I critically appraised and quality-rated all of the included studies using criteria 
modified from those recommended by the USPSTF (Table 4). I appraised studies and 
gave them a grade of good, fair, or poor based on their overall internal and external 
validity. Poor quality studies were excluded. I independently appraised quality of the 
studies; quality was not double reviewed due to the independent nature of this project. 
Table 4. Quality appraisal 
Citation Study Study No endpoint Potential for Measurement 
question& population data selection instruments 
research bias and 
design techniques 
Potential for Potential Potential for Overall External Comments 




Eligible studies reported on the consequences of following up incidental findings 
in CTC in asymptomatic average risk populations. I used standardized data collection 
forms (Tables 5 and 6) for data extraction. I first collected methodological information-
including population description and study design information. I subsequently extracted 
pertinent data from each study into standard tables. The descriptive table (Table 5) 
illustrates the study question, number and description of participants, method of selection, 
and endpoint data. The ECF results table (Table 6) illustrates data regarding the 
prevalence ofECFs, data regarding further investigations, final diagnoses, and costs. 
Although double data extraction generates fewer errors than single data extraction in 
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systematic reviews28, single review was used due to the independent nature of this 
project. 
Tbl5D 'ti a e . escnp1 ve 
Reference Study Number of Description of Method of Endpoint data 
Question Participants participants participant 
selection 
Table 6. Prevalence of ECFs 
Author Age Mean duration of Referral Findings Additional Important Estimate comments 
range f/u (Interval Process (stratified) investigations diagnoses made by of 
betweenCT & flu (and # of pts additional 
last flu check) who derived cost 
clinical benefit) 
Data Synthesis 
I performed a data synthesis that attempts to answer the following key questions: 
o Key Question # 1: What is the prevalence of all incidental findings detected on 
CTC? 
o Key Question #2: What is the prevalence of specific types of incidental fmdings? 
o Key Question #3: What are the beneficial outcomes of detecting and 
investigating incidental findings? 
o Key Question #4: What are the harms of detecting and investigating incidental 
findings? 
o Key Question #5: What are the costs and cost-effectiveness of detection and 
further investigating incidental findings? 
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I addressed these key questions quantitatively where possible. I addressed these key 




In total, I evaluated 148 abstracts and 24 full-text articles (search results are 
illustrated in Table 7. I identified 6 primary studies11• 13• 16• 19• 29• 30 and 3 systematic 
reviews3• 5• 26 that addressed the consequences of investigating extracolonic fmdings 
detected on screening CTC in average-risk asymptomatic persons from the Medline 
search. No additional studies from the other databases were included for the review. 
I excluded one ofthe 6 primary studies30 because it was poor in quality. This 
study possessed a substantial potential for confounding as nearly two-thirds ( 61.2%) of 
the population in this study were high risk with either symptoms or a personal or family 
history of colorectal polyps or cancer. This study was also limited to men, weakening its 
external validity. Two papers11• 19 from the same lead author originated from the same 
center. The most recent paper1 1 did not make it clear whether the two datasets 
overlapped. I therefore contacted the lead author, who confirmed that the first paper did 
contaminate the second. I excluded the earlier paper and did not include it in Table 8. 
I describe the features of 4 primary studies that met descriptive and quality 
criteria. All of the studies were of cross-sectional design and defined the primary goal of 
evaluating extracolonic findings detected on screening CTC in asymptomatic patients. 
One study13 examined clinical implications ofECFs with use ofiV contrast-enhanced 
CTC. 
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Table 7. QUORUM 
Potentially relevant abstracts 
identified and screened for 
retrieval(n=l48) /Articles excluded {Jrl24) 
Study relevance (n=77) 
Setting(n=2) 





Potentially appropriate articles I 
to be included in the systematic 
review; full text reviewed (n=24) 
/Studies excluded from s:~:stematic review {n=lZ} '\ 
Study relevance (n=4) 
Setting (n=l) 




Stndies included in systematic 
\..Other (n= l) / 
review (n=7) I 
4 cross .. sectional studies 
3 systematic reviews 
Quality 
Quality ratings are depicted in table 8 (A more complete table is illustrated in 
Appendix I. There were no studies with good internal validity. I rated the quality of all 
four of the included studies as fair. The main source of bias common to all included 
studies was a short duration of follow-up. 
Kimberly et al. 16 reported no endpoint data for 7 ofthe 143 (4.9%) patients due to 
insufficient EMR information, producing potential selection bias. The authors contacted 
subjects' primary care physicians (PCP) if follow-up was recommended but not 
confirmed on medical records, however they did not contact the PCP in the absence of 
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medical record confirmation for patients in whom follow-up was not recommended; this 
produced potential measurement bias. Further potential measurement bias was produced 
by imaging protocol that included two serial CTCs. Although the authors defined their 
patient population as asymptomatic, they later reported that symptoms existed in 14 
percent (19/136) of patients, producing a potential confounder. 
Pickhardt et al. 11 defined their patient population as asymptomatic, but did not 
specifY exclusion criteria. This potential selection bias may have resulted in potential 
contamination with high-risk subjects. 
Kim et al. 13 likewise did not specifY exclusion criteria, producing a potential 
selection bias by potential contamination with high-risk subjects. The authors studied 
ECFs found with IV contrast-enhanced CT. This may serve as a potential source of 
measurement bias by altering the frequency and type ofECFs found, and also by altering 
the frequency of additional investigations of certain ECFs. Use ofiV contrast-enhanced 
CTC is further discussed in the discussion section. External validity of this study is 
weakened because it was performed in Seoul, South Korea. Despite this study's 
weaknesses, I decided to include it because it also possesses a number of strengths. First, 
this study has a larger patient population than any of the other included studies; excluding 
this study would decrease the total population of the systematic review by 44. 7%. 
Second, while IV contrast-enhanced CT may serve as a potential source of measurement 
bias, this protocol may, in due course, become a standard measurement. Because of this 
very possible scenario, this study possesses a unique potential strength with in terms of 
both measurement and external validity. 
20 
All of the studies were geographically limited to either one hospitalll, 16or to a 
country outside of the United States.13• 29 These limitations decrease the generalizability 
of each study's results to the general population. 
a e . T bl 8 D escnption o tu IeS fS d' 
Reference Study Number of Description # ofECFs # of patients Mean duration of Dropouts Quality 
Question Participants of (Total) with at least follow-up (no endpoint Rating 
participants oneECF (Interval between data) 
initial CT & last 
follow-up check) 
Kimberly Evaluation 136 (data Average- 423 134 (98.5%) Median: 38 7/143 (not Fair 
of available) risk: men months (mean not enough 
extracolonic out of 143 and women (3.1 findings reported) EMRinfo) 
findings (enrolled) per patient Range: 26-45 
screened) months 
Pickhardt Evaluation 2195 Average- unspecified unspecified Mean: 544 days No loss to Fair 
of risk or Range: 190-716 follow-up 
extracolonic high-risk days 
findings men and 
women* 
Kim Evaluation 2230 Average- 2186 1484 (66.5%) Mean: 1.6 years No Joss to Fair 
of risk or Range:l-3 years follow-up 
extracolonic high-risk (0.98 
findings men and findings per 
using IV women* patient 
contrast screened) 
Chin Evaluation 432 Average- 146 118 (27.3%) 2 years (defined No loss to Fair 
of risk men in prorocol) follow-up 
extracolonic and women (0.3 findings 
findings per patient 
screened) 






*ExclusiOn cntena were not specrfied 
**Calculated using total population excluding Pickhardt et al. 
Statistical Results 
My presentation of results is arranged in accordance to the 5 key questions 
presented in the methods section. Specifically, I address the following issues: 
o Key Question #1: What is the prevalence of incidental findings detected on CTC? 
o Key Question #2: What is the prevalence of specific types of incidental findings? 
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o Key Question #3: What are the beneficial outcomes of detecting and 
investigating incidental findings? 
o Key Question #4: What are harms of detecting and investigating incidental 
fmdings? 
o Key Question #5: What are the costs and cost-effectiveness of detection and 
further investigating incidental findings? 
Key Question #1: Prevalence oflncidental Findings 
Included studies report total number ofECFs from 0.3 to 3.1 per patient with at 
least one ECF found in 62.0% of screened patients (Table 9). Findings that were 
recommended or suggested for additional investigation were found in 470 out of the 
pooled 4993 subjects (9.4%). 297 (5.9%) of all screened patients received additional 
investigation with studies reporting from 4.5-24%. All of the studies excluded previously 
known lesions and findings of previously known conditions from final analysis. 
Kimberly et al. reported 423 ECFs in 134 patients. Possible explanations for thls 
outstanding number of ECFs are further discussed in the discussion section. Of these, 
17.5% were categorized as findings of high importance, 24.5% were fmdings of moderate 
importance, and 51.7% were findings oflow importance. Thirty-two (24%) patients 
received additional investigation. 
Pickhardt et al. did not report the total number ofECFs. They reported ECFs of at 
least moderate potential clinical importance in 189 of the 2195 (8.6%) subjects that they 
observed. Of these, 157 patients (7.2% of the study's population) were recommended or 
suggested for further investigation because CT findings were sufficient for diagnoses in 
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32 patients. The deciding primary care physicians pursued further investigations in 133 
of subjects ( 6.1% of the study population), 115 for whom investigations were 
recommended or suggested and 18 for whom investigations were not recommended or 
suggested. 
Kim et al. used a protocol that utilized IV contrast-enhancement. The study 
reported 2186 ECFs in 1484 of the 2230 (66.5%) subjects that they observed. Of these, 
115 "potentially important" findings were reported in 115 patients (5.2% of the study 
population). Potentially important findings were defined as "those which required 
immediate or further diagnostic studies or medical and/or surgical treatment." Further 
investigations were pursued in 100 of these 115 patients (4.5% of study population) 
because CTC imaging was sufficient for diagnoses in 15 patients. No further 
investigations were carried out in other patients. This study reported a lower frequency 
of patients receiving additional investigation than any of the other studies. 
Chin et al. reported 146 ECFs in 118 of the 432 (27.3%) patients that they 
observed. Ofthese, 32 "clinically relevant" fmdings were reported in 32 patients. ECFs 
were defined as clinically relevant if they "required medical or surgical attention, or 
further hematological, biochemical, and/or radiological investigation after assessment." 
All of these 32 patients were further investigated. No further investigations were carried 
out in other patients. 
Protocols of the included studies define methods of referring patients for further 
investigation that can be placed in two major categories. The studies conducted by Kim 
et al. and Chin et al. defined protocols that allowed the radiologists to directly refer 
patients for further investigations. In the studies conducted by Kimberley et al. and 
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Pickhardt et al., in contrast, radiologists recommended or suggested further investigations 
to the patients' primary care physicians who were the ultimate decision-makers. In these 
two studies, there is an important lack of correlation between fmdings deemed important 
by radiologists upon detection and those that receive further investigation. Both the 
Kimberly and Pickhardt studies report a significant number of findings of high 
importance and fmdings of moderate importance that underwent no additional evaluation 
(Table 9). Both studies also reported a considerable number of findings that underwent 
further evaluation without radiologist recommendation or suggestion. Only one of the 
studies11 addressed findings that were pursued by the referring physician in the absence 
of radiologist recommendation. These authors reported that "no clinically important 
diagnoses" were established in any of these patients. The authors neither defined 
clinically important diagnoses nor described how they were determined. 
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T bl 9 R d' l . I a e . a IO OgiC mportance versus A ctua IF h I urt er nvesti~ation 
Author ECFs Findings (stratified) Received Additional 
workup 
Kimberly 423 ECFs in 134 High* - 25 ECFs in 25 Total- 32 patients (24% of 
of 136 (98.5%) patients (17.5% of study study population) 
patients population) 
High~ 14/25 (56%) 
Moderate*- 53 ECFs Moderate~ 15/35 (43%) 
in 35 patients (24.5% of Low~ 3/74 (4%) 
study population) 
Low- 345 ECFs in 74 
patients (51. 7% of study 
population) 
Pickhardt unspecified Moderate to High - Total- 133 patients (6.1% of 
189 patients (8.6% of study populatio) 
study population) 
Recommended or suggested 
Note: 157 patients ~ 115 pts 
(7.2% of study Not recommended or 
population) suggested suggested ~ 18 pts 
or recommended 
because fur 32 patients, 
CT findings were 
sufficient for diagnosis 
Kim 2186 ECFs in "Potentially Total - 100 patients (4.5% 
1484 of2230 Important"*- 115 of study population) 
patients (66.5% ECFs in 115patients 
of study (5.2% of study Note: 15 pts, CT fmdings 
population) population) were sufficient for dx 
Chin 146 ECFs in 118 "Clinically Relevant"* Total - 32 patients (7 .4% of 
of 432 patients - 32 ECFs in 32 study population) 
(27.3% of study patients (7.4% of study 
population) population) 
.. 
*Recommended or suggested for addtttonalmvesttgatmn by radtologtst 
**May include previously known lesions 
Key Question #2: Prevalence of Specific Types oflncidental Findings 
% of additional 





















strata as per 
protocol 
A number of different pathologies were ultimately diagnosed, and many treated, 
subsequent to CTC detection. The findings illustrated in Table 10 represent only the 
common mentioned fmdings in two of the studies.11• 13 The other studies 16• 29 did not 
report the specific types of findings that were ultimately diagnosed or treated following 
complete work-up. The most common diagnosed pathologies that were reported in the 
25 
two studies were nonmalignant tumors (at least 1.5% of those screened in the two 
studies), malignant tumors (0.5% of those screened in the two studies) and aortoiliac 
aneurysms (0.3% of those screened in the two studies). A more detailed description of 
specific types of findings is illustrated in Table 10. 
Table 10. Prevalence of specific types of fmdings 
Finding Number % of screened subjects 
(4425 sub.ieets)* 
Nomnalignant tumors ........................................................ at least 68 
I. Adrenal gland mass ............................................. 42t 
2. Benign ovarian tumor** ......................................... 15 
3. Retroperitoneal nenrogenic tumor .............................. I 
4. Pancreatic solid and papillary neoplasm ....................... 2t 
5. Benign hepatic mass ............................................... 3t 
6. Benign renal mass ................................................. 3t 
7. Benign prostate mass .............................................. 2t 
Malignant tumor ............................................................ .23 
I. Non-Hodgkin lymphoma ........................................ .3 
2. Renal cell carcinoma ............................................... 8 
3. Abdominal metastatic disease ................................... 2 
4. Bronchogenic carcinoma .......................................... .2 
5. Cervical .............................................................. 1 
6. Gastric adenocarcinoma ........................................... ! 
7. Hepatocellular carcinoma ........................................ .3 
8. Pancreatic adenocarcinoma ....................................... I 
9. Gastrointestinal Stromal Tumors (GIST) ....................... 2t 
Aortoiliac aneurysm ........................................................ l4 
Urolithiasis .................................................................... 6 
Hepatic eosinophilic abscess .............................................. .4 t 
Pneumonia .................................................................... .4 t 
Puhnonary ground glass opacity (GGO) ................................ At 
Pancreatic IPMT ............................................................ .4 t 
Congenital renal anomaly ................................................. .4 t 
Porcelain gallbladder ....................................................... .3 
Liver cirrhosis ............................................................... 3t 
Tuberculosis .................................................................. 2t 
Splenomegaly ................................................................ 2t 
Benign enlargement of uterus ............................................. 2t 
Mucinous adenoma of appendix ......................................... .2t 
Endometriosis ............................................................... 2t 
*these calculations consider only pooled populations in Pickhardt et a1. and Kim et al. (n=4425) 
**mucinous or serous cystadenomas or cystadenofibromas (n=7) and benign teratomas (n=8) 
tMentioned by either Kim et. al. or by Pickhardt et al., but not both 
Key Question #3: Benefits of Detection and Investigation 
At least 1.5% 
At least 0.9% 
3.5% 
0.02% 
At least 0.05% 
At least 0.07% 
At least 0.07% 










At least 0.05% 
0.3% 
0.14% 
At least O.Q9% 
At least 0.09% 
At least 0.09% 
At least 0.09% 
At least 0.09% 
0.07% 
At least 0.07% 
At least 0.05% 
At least 0.05% 
At least 0.05% 
At least 0.05% 
At least 0.05% 
A number of potential benefits may have resulted from the detection and 
investigation of incidental findings. The studies do not report the information necessary 
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to report accurate quantitative data. Some of the studies do, however, describe some 
specific examples of investigations that led to a number of pathologies that were 
diagnosed and treated. While diagnoses and treatments these findings may be of 
potential benefit, the studies provide no information regarding the ultimate outcomes. 
Thus we cannot presume that the mentioned diagnoses or treatments resulted in 
advantageous outcomes. 
Kim eta!. reported 12 malignant tumors (Table 11). Eleven of these 12 
extracolonic tumors underwent surgical resection. One (cervical cancer) was treated with 
radiation therapy. In the same report, 2 aldosterone-producing adenomas and 4 ovarian 
masses were treated surgically. Pickhardt eta!. reported that new diagnoses "of at least 
moderate clinical importance" were found in 55% of patients (2.5% of screened patients). 
The authors neither define "moderate clinical importance" nor describe how these 
diagnoses were generated. Kimberly et a!. reported that one subject who was diagnosed 
with an asymptomatic noninvasive renal cell cancer is likely to have benefited in terms of 
mortality. This study also reported that one patient with large asymptomatic bladder 
stones was referred to a urologist and eventually underwent cystoscopy. The patient 
received a transurethral dilation of the prostate and a urethral dilation to facilitate passage 
of these stones. 
At least 114 patients (2.3% of screened patients) received a clinical diagnosis with 
studies reporting from 1.9% to 2.5% (Table 11 ). At least 46 patients (0.9% of screened 
patients) underwent treatment, with individual studies reporting up to 2.0%. These 
diagnosed and treated findings may or may not be of true benefit. The true benefit of 
pursuing fmdings is unlikely to include all of the diagnosed and treated pathologies. 
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Table 11: Patients with Potential Clinical Benefit 
Author Patients with %of study # of patients %of all Total# of %of all 
Additional population who received subjects who patients who subjects who 
investigation undergoing diagnoses received received received 
further diagnoses* treatment treatment* 
investigation 
Kimberly 32 24% Not reported ? At least I ? 
Pickhardt 133 6.1% 55 2.5% Not reported ? 
Kim 100 4.5% 51 2.3% 45 2.0% 
Chin 32 7.4% 8 1.9% Not reported ? 
Total 297 5.9%* At least 114 At least 2.3%* At least 46 At least 
0.9%* 
* calculated usmg the total number of subjects (n=4993) 
Key Question #4: Harms of Detection and Investigation 
Further investigation resulted in a number of further radiological assessments, 
many of which revealed fmdings of benign nature. For example, Pickhardt eta!. reported 
that alllO patients who underwent subsequent contrast-enhanced CT or MR imaging for 
indetermiuate liver lesions were found to have benign cavernous hemangiomas of no 
clinical importance. 
Seventy-five subjects (1.5% of screened patients) received surgical or medical 
procedures, with studies reporting frequencies from 0 to 3.7% (Table 13). None of the 
studies report the comprehensive information necessary to report accurate quantitative 
values regarding the frequency of avoidable procedures. Some of the studies, do 
however, report specific examples of procedures that led to benign diagnoses. Pickhardt 
et al. reported 10 women (0.8% of all women screened) who underwent laparoscopic 
resection for complex ovarian lesions; all of which proved to be benign neoplasms. 
Although 1 bronchogenic carcinoma was found and later excised (as previously described 
in KQ#3), 3 CT -guided biopsies and 1 thoracoscopic resection resulted in 3 benign 
diagnoses. Kim eta!. reported 2 benign schwannomas diagnosed by surgery. Kimberly 
et a!. reported a total of 5 medical procedures, 4 of which proved benign diagnoses. 
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These authors reported 2 upper endoscopies for esophageal or gastric thickening; both 
revealed no abnormalities. One fiberoptic bronchoscopy with transbronchiallung biopsy 
and cultures yielded revealed no abnormality. One patient with an adnexal mass received 
a laparoscopic oophorectomy which was diagnosed as a benign ovarian cyst. 
Adverse effects including infection, hemorrhage, cardiovascular complications, 
and mortality are examples of known problems associated with invasive procedures.31 A 
number of factors influence the frequencies of these adverse effects making it difficult to 
estimate the expected frequencies of particular adverse effects that may arise with the 
implementation of widespread screening. None of the studies reported data on such 
adverse effects associated with these procedures. Various other types of harms, such as 
psychological impact and lost time from work, were not acknowledged in these studies. 
The only mention of potential harm in any of the included studies was provided by 
Pickhardt et al. who reported that no "important complications" resulted from any 
additional workup. 11 The authors offered no definition of"important complications" in 
the report. 
A comprehensive analysis on the harms of detecting ECFs is difficult to obtain 
from these studies. Considering reported data from Chin et al. and extrapolated numbers 
from Pickhardt et al. and Kim eta!. (this information could not be extrapolated from 
Kimberly et al.), an average of3.1 percent of the screened population (excluding those 
screened in Kimberly et al.) received additional investigation that resulted in no reported 
diagnosis (Table 12). Extrapolated values were obtained by subtracting the number of 
subjects who received reported (Table 11) from the number of patients who underwent 
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investigation. 0.5% of screened subjects (not including subjects in Pickhardt et al.) 
received an invasive procedure tbat resulted in benign diagnoses. 
These extrapolated values should be interpreted witb caution. Because the 
percentage of patients who received reported diagnoses represents a minimum number, 
tbese extrapolated values overestimate the true number of subjects who received further 
investigation with no reported diagnoses. The true number of subjects who received 
further investigation with no reported diagnosis underestimates the number of subjects 
who received clinical harm witb no clinical benefit. Since a certain percentage of tbose 
who received reported diagnoses ultimately receive no clinical benefit, the number of 
patients receiving harm is greater tban the true number of subjects who received further 
investigation witb no reported diagnoses. The numbers of further investigations and 
invasive procedures tbat result in no reported diagnoses should furthermore be interpreted 
in a different manner tban those tbat describe potential benefits. All ofthe patients who 
received further investigations with no diagnoses or treatment experienced at least some 
degree of anxiety or lost time that would have been avoided if the findings had not been 
detected. All of the patients who received invasive procedures likewise experienced at 
least some degree of pain, anxiety, and lost time. 
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Table 12. Additional investi ations resulting in no clinically important diagnoses 
Author Patients with # of patients who received %of study population who 
Additional additional workup with no received additional workup 
investigation reported diagnoses with no reported diagnoses 
Kimberly 32 ? ? 
Pickhardt 133 78* 3.6%* 
Kim 100 49* 2.2%* 
Chin 32 24 5.6% 
Total 297 151** 3.1%** 
*These numbers were not reported m the studies but were obtamed by subtractmg the number of pattents who 
received clinically important diagnoses or treatment (see Table 11) from the number of patients with additional 
investigation 
**These nnmbers considered the data included in Pickhardt it a!., Kim eta!., and Chin eta!. but not Kimberly et 
a!. (n=4859) 
Table 13. I nvasiVe proc ed ures resu ting m I . b fi d. enlgn m mgs 
Author # of invasive %of study # of invasive % of invasive %of study Ml\iorharms 
procedures population procedures resulting procedures population who reported 
receiving in benign findings resulting in received an 
procedures benign invasive 
findings procedure with 
benign fmding 
Kimberly 5 3.7% 4-5* 80-100% 2.9-3.7% 




29 1.3% 9** 31.0% 0.4o/O-
0 0% 0 NIA 0 
75 1.5% At least 13 ** 38.2%*** 0.5%t 
*one procedure a1ded passage of an asymptomatic bladder stone that had the potenttal to cause symptoms down 
the road 
**It is difficult to assess whether or not some procedures are necessary or unnecessary. 
***These numbers did not consider data from Pickhardt et al. (denominator= 34 invasive procedures) 
t These numbers did not consider data from Pickhardt eta!. (n~2798) 
Key Question #5: Costs and Cost-effectiveness of Detection and Further 
Investigation 






cost of further investigation. Kim et al calculated only imaging costs (Table 14). Chin et 
a! reported no procedures in their results; a larger study population would likely have led 
to a number of performed procedures which would have heavily influenced the calculated 
cost. 
True cost estimates of additional workup likely fall between $98.56 (reported by 
Pickhardt et al.) and $248 (reported by Kimberly et al.) per person screened. The 
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calculation reported by Pickhardt et al is based on a large population but does not include 
costs of referrals and return visits, therefore likely underestimating the true cost. Costs 
calculated by Kimberly et al. reflects additional radiographic studies, laboratory studies, 
medical procedures, referrals and return visits that resulted solely from ECFs. Assuming 
that the estimate provided by Pickhardt et al. is a reasonably accurate reflection of costs 
without referrals and return visits, it is unlikely that referrals and return visits are 
responsible for the 60% difference in cost reported by Kimberly et al. Therefore this 
small-scale study may have overestimated the true cost. 
A cost-effectiveness analysis cannot be properly performed without a more 
thorough understanding of the true benefits and harms. 
Table 14. Costs 
Author Additional cost of Country Included in cost analysis 
investigating ECFs 
(per patient screened) 
Kimberly $248 United States Radiological studies, laboratory studies, 
medical procedures, referrals & return visits 
Pickhardt $98.56 United States Radiological studies, laboratory studies, 
medical procedures 
Kim $2.34 Korea Radiological studies only 
Chin $24.37 Australia Radiological studies, laboratory studies, 
clinical evaluation 
Synthesis of Evidence 
At least one newly found ECF was detected in 62.0% of screened patients 
(KQ# 1 ). Many differences existed between the studies, including differences in 
categorization of importance, varying measurement protocols, and differences in referral 
methods. 297 patients (5.9% of the total screened population) received additional 
investigations. 
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The most common diagnosed pathologies (KQ #2) are nonmalignant tumors, 
which occurred in at least 1.5% of screened patients. Malignant tumors were diagnosed 
in 0.5% of screened patients, and aortoiliac aneurysms were diagnosed in 0.3% of 
screened patients. 
The true benefits of detecting incidental findings (KQ#3) remain unclear. The 
studies provide no information regarding the ultimate outcomes. At least 2.3% of 
screened patients received a clinical diagnosis and at least 0.9% of screened patients 
underwent treatment. The true benefit of detecting and pursuing findings is unlikely to 
include all of the diagnosed and treated pathologies. 
An accurate report of the adverse effects (KQ#4) is difficult to interpret from 
these studies. The included studies made little to no mention regarding adverse effects. 
A number of patients received additional imaging and invasive procedures. An average 
of 3.1% of screened patients received additional investigation that resulted in no reported 
diagnosis. This value may overestimate the true number of additional investigations that 
resulted in no reported diagnoses. 0.5% of screened subjects received an invasive 
procedure that resulted in benign diagnoses. The true numbers of patients who received 
no reported diagnoses after further investigations represent the minimum number of 
patients who received at least some degree of harm with no benefit. 
The cost of pursuing incidental findings (KQ#S) likely falls between $98.56 and 
$248. Cost-effectiveness analysis carmot be assessed without a more comprehensive 




I found no randomized trials that evaluated the consequences of investigating 
extracolonic findings on CTC screening. I therefore evaluated the available literature 
with five key questions that focused on the prevalence, benefits, harms, and costs of their 
detection and follow-up. 
Incidental lesions were found in 62% of screened patients and 5.9% of the total 
screened population received additional investigations. The number of incidental 
findings varied between studies. Kimberly et al. reported a much higher frequency of 
ECFs than did the other studies. The authors attributed this difference to a measurement 
protocol that included the use of 2 CTCs serially and a protocol that did not minimize 
visualized lung parenchyma. The local training and practices of the radiologists 
influenced which findings warranted being reported. For example, degenerative disease 
of the spine was the second most common fmding in Kimberly et al., whereas this finding 
wasn't reported in any subjects in other studies. Differences in reporting may 
significantly alter the frequency of fmdings. These effects are particularly manifested 
given that each of the studies was performed in one to two centers. 
The frequency of detection was not a strong predictor of either additional pursued 
investigation. For instance, though Kim et al. reported over two times the frequency of 
patients with ECFs as Chin eta!. (66.5% and 27.3%, respectively), they reported a lower 
frequency of additional investigation per patient ( 4.5% and 7.4%, respectively). One 
important factor contributing to the lack of correlation is differences in referral practices. 
Protocols used by Kim et al. and Chin et al. gave final decision-making responsibility to 
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radiologists whereas protocols used by Kimberly eta!. and Pickhardt eta!. gave the final 
responsibility to the patients' primary care physicians. Furthermore, data from the 
studies that gave decision-making responsibility to the primary care physicians 
demonstrated a low correlation between those deemed important by the radiologist and 
those that the primary care physician selected to investigate. 
Kim et al. studied ECFs with the use of IV contrast-enhancement, claiming that it 
is harder to characterize lesions without contrast material, which leads to unnecessary 
further evaluation. IV contrast-enhancement improves the specificity, conveys greater 
information than non-contrast exarns/6 and enables the radiologist to distinguish between 
solid and cystic lesions. 13 This method may permit identification and characterization of 
additional unexpected abnormalities. 32• 33 Use of IV contrast decreases the percentage of 
poorly defined lesions and increases the number of complete diagnosed lesions- yielding 
more clear diagnoses. Therefore, use ofiV contrast may decrease the number of further 
investigations by reducing incompletely characterized lesions.11• 13• 35 The frequency of 
patients with at least one ECF was 66.5%, comparable with the average of all of the 
included studies ( 62.0% of screened subjects). The frequency of patients receiving 
additional investigation ( 4.5% of screened subjects) is lower than that of any of the other 
studies included in this review. While decreased frequency of additional investigations 
may be a potential benefit ofiV contrast-enhancement, it also includes potential 
limitations such as additional costs, longer time, invasiveness, higher radiation dose, and 
increased risk of adverse reactions to contrast agents. 32 
The overall benefit of detecting incidental findings remains unclear, mainly 
because none of the studies provide information regarding ultimate outcomes. At least 
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2.3% of screened patients received a clinical diagnosis and at least 0.9% of screened 
patients underwent treatment. The true benefit of detecting and pursuing findings is 
likely to include some, but not all, of the diagnosed and treated pathologies. 
While the included studies made little mention regarding adverse effects, it is 
clear that a number of patients experienced at least some degree of harm with no benefit. 
A number of patients received additional imaging and invasive procedures. 
Approximately 3.1% of patients received additional investigation that resulted in no 
reported diagnosis, though this may be an overestimate of the true value. At least 0.5% 
of screened subjects received an invasive procedure that resulted in benign diagnoses. 
All patients who receive further investigation with no diagnosis receive at least some 
degree of harm. 
Comparison to Past Relevant Studies 
I located three systematic reviews that address the consequences of following up 
ECFs incidentally found on CT colonography. 3• 5• 26 These reviews focused largely on 
prevalence of nature of the fmdings. None of these systematic reviews reported data 
regarding harm or investigations that resulted in benign findings. 
A 2005 systematic review conducted by Xiong et al. 3 examined 9 studies that 
examined the nature and frequency of incidental findings on CTC. The frequency of 
screened patients with incidental findings in this review was similar to that of Xiong et al. 
(62% and 58%, respectively). This review reported a lower frequency of additional 
investigation than the review conducted by Xiong et al. (5.9% and !3.8% of screened 
populations, respectively) and a higher number of screened subjects who received 
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treatment (at least 0.9% and 0.8% of screened subjects, respectively) than in the report by 
Xiong et al. However, Xiong et al. described these as findings that "needed immediate 
treatment." The authors did not offer a precise definition of"immediate treatment." The 
two most common findings were cancer and aortoiliac aneurysms in both this study and 
that of Xiong et al. (2.4% and 3.7% of screened subjects, respectively, had either cancer 
or an aortoiliac aneurysm). In contrast to this study, the majority of the studies in 
included by Xiong et al. used symptomatic patients rather than those with a population 
risk for colorectal cancer. 
In a 2008 systematic review, Siddiki et al.26 examined the frequency, 
categorization, and spectrum of incidental findings. The authors reported separate data 
for symptomatic and asymptomatic populations. The frequency of asymptomatic patients 
with incidental findings reported by Siddiki et al. was slightly lower than that reported in 
this review (53% weighted mean and 62% respectively). Siddiki et al. reported similar 
frequency ofECFs requiring further investigation as this review (5-8% and 5.9% 
respectively). Siddiki et al. reported 1.3 - 2.3% of asymptomatic screened patients 
underwent subsequent medical or surgical intervention. Some of the asymptomatic 
populations included in the Siddiki review14• 30• 34• 35 include high risk patients and 
therefore likely overestimate the prevalence and importance ofECFs in an average-risk 
population. 
In a 2008 USPSTF systematic review for colorectal cancer screening, Whitlock et 
al. 5 reported the frequency ofECFs of high importance (4.5% to 11% in screened 
subjects), ECFs of moderate clinical significance (up to 27% in screened subjects), and 
recommended additional evaluation (7% to 16% in screened subjects) in asymptomatic 
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populations. The report did not investigate the number of patients that underwent further 
investigation. The authors reported that a minority of those recommended ultimately 
warranted definitive treatment, though no quantitative value was offered. Many studies 
in the Whitlock review included high-risk subjects. 
Public Health Implications 
This systematic review examined the studies with the highest available quality 
that addressed the average-risk asymptomatic populations that are recommended to 
receive colorectal cancer screening. The data in this review is insufficient to 
comprehensively examine benefits and harms and thus adds to the current body of 
evidence that we do not know how to suitably handle incidental extracolouic CTC 
findings. 
Future Studies 
Endorsements for CTC use for screening will be more likely to occur with the 
minimization of uncertainties (i.e. such as incidental findings), increased cost-
effectiveness, and most importantly, evidence of improved ultimate outcomes. An 
understanding of CTC assessment methodology offers a perspective on how future 
studies may be performed in a more pragmatic manner that allows us to utilize CTC 
while minimizing uncertainties and costs by eliminating the visualization of extracolouic 
fmdings. 
CTC images are reviewed using 2D multiplanar images and 3D endolumenal 
displays of the colon.3 The 3D endolumenal ("flythrough") display illustrates the inside 
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of the colon, as does conventional video colonoscopy (hence the nickname "virtual 
colonoscopy"). 3D endolumenal displays are assessed separately from the 2D 
multiplanar images. Assessment of 2D axial images is not necessary for the 
identification of colon polyps; it is used to examine extralumenal structures and some 
diffuse colonic diseases.36 Therefore assessment of3D endolumenal display only (with 
the elimination of2D multiplanar assessment) presents a modality most similar to the 
gold standard colonoscopy without the visualization incidental findings. 
A head-to-head randomized controlled trial (RTC) comparing colonoscopy to 3D 
endolumenal displays (with the elimination of2D multiplanar assessment) will give us a 
more accurate assessment of the value of CTC for the pathology in question- colorectal 
cancer. The ultimate benefits and harms of interest are numerous, complex, and difficult 
to extrapolate with prevalence studies. A trial will provide direct data of the desired 
ultimate outcomes such as mortality reduction. Assessment of 3D endolumenal displays 
with 2D multiplanar assessment as a third arm can provide valuable preliminary 
information of the true consequences of pursuing incidental findings. 
In addition to eliminating the uncertainties that accompany detection of incidental 
fmdings, a trial that examines the assessment exclusively of3D endolumenal displays 
may demonstrate improved feasibility for widespread implementation given decreased 
costs and increased expedience. Furthermore, it has been suggested that the common 
finding of incidental lesions may lower the utility of CTC. Removing the detection of 
these findings may therefore improve one of the largest limitations of colorectal cancer 
screening- adherence. 
39 
Examining scans for incidental findings and reporting them represents a non-
trivial investment in time, study design, and resources by CTC research teams. 
Researchers have previously addressed the potential of disregarding extracolonic 
findings. Some researchers cite the importance of moral and legal obligations to pursue 
incidental fmdings, including respect for persons and the researcher's duty to warn of 
foreseeable harm.26 Pickhardt eta!. state that withholding or not reviewing imaged 
regions raises clinical and ethical concerns, especially given the potential that a relevant 
finding is harbored.11 If a trial does, however, demonstrate a benefit exclusive 3D 
endolumenal examination over conventional colonoscopy, these ethical and medicolegal 
obstacles will be challenged. 
Defining a standard protocol for pursuing incidental findings will likely prove to 
be a long and tedious venture. Such an undertaking should be reserved until CTC 
demonstrates improved outcomes with exclusive use for colorectal pathology. 
Strengths and Limitations 
A strength that distinguishes this systematic review apart from others is that it 
studies an average-risk population by excluding studies that examined only symptomatic 
patients, high-risk patients, and elderly patients. I was unable to locate any other review 
that exclusively examined an average-risk population. 
This review has some limitations. First, the review included a small number of 
studies and a relatively small patient population. Second, all of these studies were cross-
sectional studies and were fair in quality. All of the included studies reported a short 
duration of follow-up that is responsible for considerable measurement bias. Third, I 
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limited the search to English-language articles, and therefore I may have excluded studies 
from similar non-English-speaking populations. Fourth, none of the studies appropriately 
addressed the harms of CTC. 
Conclusions and Summary of Main Findings 
Some clinical benefit may arise from pursuing ECFs. Some important 
pathologies were ultimately detected and many were treated. We cannot conclude that 
the early detection and treatment of the ECFs during asymptomatic phases confers a 
benefit over diagnostic evaluation and treatment in later symptomatic phases. This 
review cannot offer an accurate estimate of true clinical benefit of pursuing ECFs. No 
studies have evaluated the harms of pursuing ECFs so we likewise cannot calculate an 
appropriate estimate of the true harm. We do know that a number of additional 
investigations and procedures were pursued that resulted in benign diagnoses. From 
these, we can presume that pursuing ECFs produces at least some degree of harm. 
Importantly, we cannot estimate the varying degrees of benefits and harms. Available 
studies, therefore, do not bring us closer to settling the central key issue - weighing the 
overall benefits versus the harms. 
CTC screening has the potential to make a significant impact on colorectal cancer 
screening. Our understanding of how to handle ECFs remains far from where it needs to 
be if CTC were to become a modality recommended for widespread screening. A trial is 
therefore warranted to provide a more comprehensive and accurate assessment of the 
desired ultimate beneficial and harmful outcomes. 
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Prior to extensive assessment of how to handle incidental findings, we should first 
perform a basic evaluation of CTC for the pathology in question- precancerous 
colorectal polyps- in the absence of incidental findings. A trial comparing colonoscopy 
with the exclusive assessment of 3D endolumenal display CTC will offer the most 
pertinent data to assess the true ability of CTC to confer a benefit over colonoscopy 
regarding colorectal cancer. 
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Appendix A- Quality Appraisal 
Table 1: Quality appraisal of Kimberly et al. 
Citation Study question Source & Study No endpoint Potential for Measurement 
& research population data selection bias instruments and 
desi~n techniques 
Kimberly, et Evaluation of Patients at one 71143 (not ++ Two serial CTCs 
aL extracolonic large university enough 
2008 findings medical center EMRinfo) Contacted PCP if 5mm collimation 
referred for follow-up was 
Cross- colonoscopy recommended but PCP pending 
sectional screening. 40 not confirmed on radiologist 
y/o or older. medical record; recommendation 
Excluded if did not contact or suggestion 
higb risk or PCP in the 
presence of absence of Short duration of 
illness medical record follow-up 
precluding confirmation for 
participation. patients in whom 
follow-up was not 







Potential for Potential Potential for Overall External validity Comments 
measurement confounders confounding judgment of 
bias internal 
validity 
+++* Some elderly ++ Fair Fair Costs include 
patients imaging, 
included Study performed laboratory tests, 
at only I hospital procedures, and 
some patients -radiologist referrals and 
reported training and retum visits. 
symptoms at hospital-specific 
baseline protocols may not 
be generalizable 
* Short duration of follow-up is responsible for higb degree of measurement bias. This unavoidable source 
ofbias will not preclude inclusion of study into the review. 
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Table 2: Quality appraisal of Pickbardt et al. 
Citation Study question Soun:e&Study No Potenfull for Measurement 
& research population endpoint selection bias instruments and 
desi2n data tecboiques 
Pickhardt et Evaluation of Asymptomatic No loss to ++ 1.25mm 
al. extracolonic patients at one follow-up collimation 
2008 fmdings large university methodofpt 
medical center selection not PCP pending 
Cross- referred for described radiologist 
sectional colonoscopy thoroughly recommendation or 
screening. 40 y/o suggestion 
or older. 
Asymptomatic Short duration of 
adults. Exclusion follow-up 
criteria not 
specified. 
2 I 95 consecutive 
patients 
Potenfull for Potential Potential for Overall External Comments 
m~asurement confounders confounding judgment of validity 
bias internal 
validitv 
++* Some elderly ++to+++ fair Fair Cost only includes 
patients imaging, labs, and 
included Study procedures. 
performed at Referrals and 
Possible only I hospital return visits not 
inclusion of - radiologist included. 
high-risk training and 
patients hospital-
specific 
Gender- protocols may 
(54.7% not be 
female) generalizable 
*Short duration of follow-up is responsible for high degree of measurement bias. This unavoidable source 
of bias will not preclude inclusion of study into the review. 
50 
Table 3: Quality appraisal of Kim et al. 
Citation Study question Source & Study No Potential for Measurement 
& research population endpoint selection bias instruments and 
desi2n data technioues 
Kim et al. Evaluation of Asymptomatic No loss to ++ all potentially 
2007 extracolonic patients at one follow-up important findings 
findings large university methodofpt referred for follow-
using IV medical center selection not up by radiologists; 
contrast referred for described those not followed 
colonoscopy thoroughly were still monitored 
Cross-sectional screening. 50 y/o and many were 
or older. followed up later 
Asymptomatic 
adults. Exclusion IV -contrast 
criteria not enhancedCT 
specified. 
0. 75mm collimation 
2230 consecutive Referral direct from 
patients radiologist 
Short duration of 
follow-up 
Potential for Potential Potential for Overall External Comments 
measurement confounders confounding judgment validity 
bias of internal 
validity 
+++* Some elderly ++to+++ Fair Fair/poor IV contrast-
included enhanced CT not 
Study excluded because 
Possible performed in there currently is no 
inclusion of Seoul, Korea gold standard for 
high-risk CTC protocol. 
patients 
Cost data derived 
Gender(60% from Korean 
men) National Health 
Insurance Act and 
Enforcement 
Ordinance and 
calculated in US 
dollars at the 2004 
basic exchange rate. 
Cost only includes 
imaging. 
Procedures, labs, 
referrals and return 
visits not included. 
* Short duration of follow-up is responsible for high degree of measurement bias. This unavoidable source 
of bias will not preclude inclusion of study into the review. 
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Table 4: Quality appraisal of Chin et al. 
Citation Study question Source & Study No Potential for Measurement 
& research population endpoint selection bias instruments and 
desi~n data techniques 
Chin et al. Evaluation of Asymptomatic No loss to + Referral dire<:t 
2005 extracolonic p<Jrticipants in two follow·up from radiologist 
findings community-based well described 
Cross~sectional colorectal method of 5mm collimation; 
neoplasia selection 3mm collimation 
screening 
Short duration of programs by CTC; 
both groups follow-up 
randomly drawn 
from Australian 
database. 50 y/o 
or older. 
Excluded if high 





Potential for Potential Potential for Overall External validity Comments 
measurement confounders confounding judgment 
bias of internal 
validity 
+++* + Fair Fair No procedures 
were reported in 
Study this study; this 
performed in likely influences 
Austrailia cost calculations. 
Cost does include 
referrals and return 
visits. 
*Short duratJon of follow-up ts responstble for htgh degree of measurement btas. Thts unavotdable source 
of bias will not preclude inclusion of study into the review. 
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